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ESMO Minimum Clinical Recommendations for the diagnosis,
treatment and follow-up of chronic myelogenous leukemia
(CML)
Incidence
. The incidence according to the SEER data is 1.38/100 000
per year. The mortality is 0.74/100 000 per year. The
median age at diagnosis is around 60 years.
Diagnosis
. Myeloid hyperplasia associated with splenomegaly and neu-
trophil leukocytosis, thrombocytosis and basophilia are typi-
cal features of CML in its initial chronic phase.
. In almost all patients, blood and marrow cells carry the
specific chromosomal translocation t(9;22), the Philadelphia
chromosome, or its variants.
Staging and risk assessment
. The major risk is the transformation of the initial chronic
into the blastic phase of the disease characterized by >_30%
blasts in blood or marrow, or >_50% blasts and promyelo-
cytes in marrow, or extra-medullar blastic infiltration. An
accelerated phase (transitional from chronic to blastic
phase) is defined as 15–29% blasts in marrow or blood, or
30–49% blasts plus promyelocytes in marrow.
. Prognostic scores based on age, spleen size, and blood cell
counts have been developed that allow the discrimination of
patient subgroups with different prognosis on cytoreductive
chemotherapy and on interferon, respectively.
Treatment
. The only curative treatment available is allogeneic stem cell
transplantation. Younger patients, especially those with
unfavorable risk factors, should be considered for this treat-
ment at diagnosis. The patient should be involved in the
decision process, which must balance the chance of cure
against the risk of transplant-related mortality.
. The tyrosine kinase inhibitor imatinib is highly effective in
inducing hematologic and cytogenetic remissions [I, A].
Imatinib (400mg p.o. daily) is first-line standard therapy
because of better tolerance, a much higher cytogenetic
response rate, and a lower progression rate to accelerated or
blastic phase compared with interferon-/ara-C-based therapy.
However, its long term efficacy is not yet known [I, A].
. In good prognosis patients, interferon-a at doses of
3–5MU/m2 daily may be considered as an alternative
treatment.
. The clinical benefit of intensive chemotherapy with or with-
out autologous stem cell transplantation is not proven.
. If the treatment goal is only to relieve symptoms, hydro-
xyurea may be considered [II, A].
Follow-up
. Patients are followed by blood cell counts once weekly
during the first weeks of therapy and every 1–2 months
later on. Bone marrow cytogenetics (and/or quantitative
PCR of bcr/abl) should be performed in imatinib-treated or
interferon-treated patients every 6 months. Patients relapsing
after allotransplant may still have curative options, e.g.
donor lymphocyte transfusions, and require more frequent
controls.
Note
Levels of Evidence [I–V] and Grades of Recommendation
[A–D] as used by the American Society of Clinical Oncology
are given in square brackets. Statements without grading were
considered justified standard clinical practice by the experts
and the ESMO faculty.
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